Ann Coloproctol > Volume 37(4); 2021 > Article |
|
Variable |
Before propensity score matching |
After propensity score matching |
||||
---|---|---|---|---|---|---|
NAC (+) (n=66) | NAC (–) (n=363) | P-value | NAC (+) (n=60) | NAC (–) (n=60) | P-value | |
Age (yr) | 54 ± 11 | 60 ± 12 | < 0.001 | 53 ± 11 | 56 ± 11 | 0.098 |
Body mass index (kg/m2) | 23.2 ± 2.8 | 23.4 ± 2.9 | 0.519 | 23.2 ± 2.8 | 23.1 ± 2.7 | |
Sex | 0.489 | 0.752 | ||||
Male | 37 (56.1) | 220 (60.6) | 31 (51.7) | 35 (58.3) | ||
Female | 29 (43.9) | 143 (39.4) | 29 (48.3) | 25 (41.7) | ||
Preoperative CEA (ng/mL) | 0.607 | 0.854 | ||||
<5 | 35 (53.0) | 180 (49.6) | 34 (56.7) | 33 (55.0) | ||
≥5 | 31 (47.0) | 183 (50.4) | 26 (43.3) | 27 (45.0) | ||
ASA PS classification | 0.691 | 0.697 | ||||
I, II | 62 (93.9) | 336 (92.6) | 56 (93.3) | 57 (95.0) | ||
III, IV | 4 (6.1) | 27 (7.4) | 4 (6.7) | 3 (5.0) | ||
Pathology T stage | 0.001 | 0.762 | ||||
T1/T2 | 10 (15.2) | 16 (4.4) | 7 (11.7) | 5 (8.3) | ||
T3/T4 | 56 (84.8) | 347 (95.6) | 53 (88.3) | 55 (91.7) | ||
Pathology N stage | 0.749 | 0.452 | ||||
N0 | 12 (18.2) | 73 (20.2) | 9 (15.0) | 13 (21.7) | ||
N1 | 29 (43.9) | 137 (37.7) | 26 (43.3) | 20 (33.3) | ||
N2 | 25 (37.9) | 153 (42.1) | 25 (41.7) | 27 (45.0) | ||
Segmental involvement | < 0.001 | 0.539 | ||||
1 | 15 (22.7) | 199 (54.8) | 15 (25.0) | 22 (36.7) | ||
2 | 21 (31.8) | 107 (29.5) | 20 (33.3) | 15 (25.0) | ||
3 | 9 (13.6) | 24 (6.6) | 8 (13.3) | 8 (13.3) | ||
≥4 | 21 (31.8) | 33 (9.1) | 17 (28.3) | 15 (25.0) | ||
Location of primary tumor | 0.225 | 0.367 | ||||
Right colon | 10 (15.2) | 89 (24.5) | 8 (13.3) | 14 (23.3) | ||
Left colon | 35 (53.0) | 180 (49.6) | 33 (55.0) | 29 (48.3) | ||
Rectum | 21 (31.8) | 94 (25.9) | 19 (31.7) | 17 (28.4) | ||
Size of primary tumor (cm) | 3.9 ± 2.0 | 5.4 ± 2.0 | < 0.001 | 4.0 ± 2.0 | 4.3 ± 2.1 | 0.660 |
Liver metastatic lesion sizea (cm) | 2.6 ± 1.9 | 2.5 ± 1.2 | 0.434 | 2.7 ± 2.0 | 2.4 ± 1.2 | 0.335 |
Values are presented as number (%) or mean±standard deviation if otherwise specified.
NAC, neoadjuvant chemotherapy; NA, not applicable; FOLFOX, fluorouracil, leucovorin, oxaliplatin; FOLFIRI, fluorouracil, leucovorin, irinotecan; XELOX, capecitabine, oxaliplatin; XELIRI, capecitabine, irinotecan; MSI, microsatellite instability; MSS, microsatellite stable; MSI-H, MSI high; MSI-L, MSI low.
Target agent: bevacizumab or cetuximab.
Variable |
Before propensity score matching |
After propensity score matching |
||||
---|---|---|---|---|---|---|
NAC (+) (n=66) | NAC (–) (n=363) | P-value | NAC (+) (n=60) | NAC (–) (n=60) | P-value | |
Hepatectomy | < 0.001 | 0.715 | ||||
Majora | 36 (54.5) | 114 (31.4) | 32 (53.3) | 30 (50.0) | ||
Minorb | 30 (45.5) | 249 (68.6) | 28 (46.7) | 30 (50.0) | ||
Primary tumor resection | 0.042 | 0.307 | ||||
RHC | 11 (16.7) | 88 (24.2) | 9 (15.0) | 11 (18.3) | ||
LHC | 0 (0) | 20 (5.5) | 0 (0) | 2 (3.3) | ||
AR/LAR/uLAR/ISR | 55 (83.3) | 255 (70.3) | 51 (85.0) | 47 (78.4) | ||
Surgical approach | 0.121 | 0.850 | ||||
Open | 42 (63.6) | 265 (73.0) | 38 (63.3) | 37 (61.7) | ||
MIS | 24 (36.4) | 98 (27.0) | 22 (36.7) | 23 (38.3) | ||
Stoma formation | 13 (19.7) | 44 (12.1) | 0.095 | 13 (21.7) | 6 (10.0) | 0.080 |
Variable |
Before propensity score matching |
After propensity score matching |
||||
---|---|---|---|---|---|---|
NAC (+) (n=66) | NAC (–) (n=363) | P-value | NAC (+) (n=60) | NAC (–) (n=60) | P-value | |
Operation time (min) | 336 ± 112 | 297 ± 103 | 0.005 | 334 ± 112 | 312 ± 120 | 0.304 |
Transfusion | 10 (15.2) | 49 (13.5) | 0.720 | 9 (15.0) | 10 (16.7) | 0.803 |
Time to soft diet (day) | 2.9 ± 1.4 | 3.0 ± 1.2 | 0.852 | 2.8 ± 1.2 | 2.8 ± 1.0 | 0.869 |
Length of hospital stay (day) | 14±8 | 14±8 | 0.993 | 14±9 | 13±7 | 0.687 |
Postoperative mortality (< POD 30)a | 0 (0) | 2 (0.6) | 0.546 | 0 (0) | 0 (0) | > 0.999 |
Postoperative morbidity | 24 (36.4) | 132 (36.4) | > 0.999 | 22 (36.7) | 23 (38.3) | 0.850 |
Bile leakage | 2 (3.0) | 9 (2.5) | 0.680 | 2 (3.3) | 4 (6.7) | 0.402 |
Surgical site infection | 9 (13.6) | 49 (13.5) | 0.976 | 8 (13.3) | 6 (10.0) | 0.570 |
Ileus | 7 (10.6) | 37 (10.2) | 0.919 | 5 (8.3) | 4 (6.7) | 0.729 |
Anastomotic leakage | 2 (3.0) | 19 (5.2) | 0.755 | 2 (3.3) | 3 (5.0) | 0.648 |
Intraabdominal fluid collection | 4 (6.1) | 21 (5.8) | 0.930 | 4 (6.7) | 4 (6.7) | > 0.999 |
Intraabdominal bleeding | 1 (1.5) | 5 (1.4) | 0.930 | 1 (1.7) | 2 (3.3) | 0.559 |
Timing of Adjuvant Chemotherapy in Colorectal Cancer Patients2013 August;29(4)